Comparative Pharmacology
Head-to-head clinical analysis: GYNE LOTRIMIN versus MYCELEX 7.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GYNE LOTRIMIN versus MYCELEX 7.
GYNE-LOTRIMIN vs MYCELEX-7
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clotrimazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This disrupts membrane integrity and function, leading to fungal cell death.
Clotrimazole, an azole antifungal, inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and increasing membrane permeability.
Intravaginal: clotrimazole 500 mg vaginal tablet once or 200 mg vaginal tablet daily for 3 days or 1% vaginal cream 5 g daily for 7–14 days. Topical: clotrimazole 1% cream applied to affected area twice daily for 2–4 weeks.
Clotrimazole 100 mg vaginal tablet inserted intravaginally once daily at bedtime for 7 days.
None Documented
None Documented
The terminal elimination half-life of clotrimazole is approximately 3.5-4.9 hours. However, after topical application, systemic absorption is minimal, and local concentrations persist for hours to days at the site of action.
The systemic half-life of clotrimazole following vaginal administration is approximately 0.5–1 hour due to rapid metabolism and elimination. This short half-life reflects minimal systemic absorption (3–10%).
Primarily fecal (approx. 90%) as unchanged drug and metabolites; renal excretion accounts for <1% of absorbed dose.
Primarily via feces as unchanged drug (approx. 50%) and metabolites. Renal excretion of unchanged drug is minimal (<1%) as the drug is poorly absorbed from the vagina. Biliary excretion contributes to fecal elimination.
Category C
Category C
Azole Antifungal
Azole Antifungal